Estrella Immunopharma Appoints New CMO & CSO, CMO Departs
Ticker: ESLAW · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1844417
| Field | Detail |
|---|---|
| Company | Estrella Immunopharma, INC. (ESLAW) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $11.50, $5,000, $2,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Estrella Immunopharma reshuffled its medical and science leadership, bringing in new execs and saying goodbye to another.
AI Summary
Estrella Immunopharma, Inc. announced on August 14, 2024, the appointment of Dr. Jianjun Liu as Chief Medical Officer and Dr. Hongbo Li as Chief Scientific Officer. The company also reported the departure of Dr. Alexey V. Aleshin as Chief Medical Officer. These changes are effective immediately.
Why It Matters
Key leadership changes in medical and scientific roles can signal shifts in the company's research and development strategy or pipeline focus.
Risk Assessment
Risk Level: medium — Changes in key scientific and medical leadership can introduce uncertainty regarding the company's strategic direction and execution.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- Dr. Jianjun Liu (person) — Appointed Chief Medical Officer
- Dr. Hongbo Li (person) — Appointed Chief Scientific Officer
- Dr. Alexey V. Aleshin (person) — Departed Chief Medical Officer
- August 14, 2024 (date) — Effective date of appointments and departure
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jianjun Liu has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Scientific Officer?
Dr. Hongbo Li has been appointed as the new Chief Scientific Officer.
Who has departed from the role of Chief Medical Officer?
Dr. Alexey V. Aleshin has departed from the role of Chief Medical Officer.
What is the effective date of these personnel changes?
The changes are effective immediately as of August 14, 2024.
What is the company's primary business sector?
Estrella Immunopharma, Inc. is in the Biological Products sector.
Filing Stats: 966 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2024-08-20 17:00:50
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
- $5,000 — Ms. Zhang will receive compensation of $5,000 per calendar quarter for her service as
- $2,500 — service as a director and an additional $2,500 per calendar quarter for her service as
Filing Documents
- ea021197101-8k_estrella.htm (8-K) — 34KB
- ea021197101ex99-1_estrella.htm (EX-99.1) — 10KB
- 0001213900-24-071174.txt ( ) — 271KB
- esla-20240814.xsd (EX-101.SCH) — 4KB
- esla-20240814_def.xml (EX-101.DEF) — 27KB
- esla-20240814_lab.xml (EX-101.LAB) — 37KB
- esla-20240814_pre.xml (EX-101.PRE) — 25KB
- ea021197101-8k_estrella_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits 99.1 Press Release issued by Estrella Immunopharma, Inc. on August 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ESTRELLA IMMUNOPHARMA, INC. Date: August 20, 2024 By: /s/ Cheng Liu Name: Cheng Liu Title: Chief Executive Officer